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High mobility group box 1 (HMGB1) is an ubiquitous protein that plays different roles in the nucleus, cytoplasm, and extracellular
space. It is an important DAMP molecule that allows communication between damaged or tumor cells and the immune system.
Tumor cells exploit HMGB1’s ability to activate intracellular pathways that lead to cell growth and migration. Papillary thyroid
cancer is a well-differentiated tumor and is often used to study relationships between cells and the inflammatorymicroenvironment
as the latter is characterized by high levels of inflammatory cells and cytokines. Anaplastic thyroid cancer is one of the most lethal
human cancers in which many microRNAs and tumor suppressor genes are deregulated. Upregulation of microRNAs 221 and 222
has been shown to induce the malignant phenotype in many human cancers via inhibition of PTEN expression. In this study we
suggest that extracellular HMGB1 interactionwith RAGE enhances expression of oncogenic clustermiR221/222 that in turn inhibits
tumor suppressor gene PTEN in two cell lines derived from human thyroid anaplastic and papillary cancers. The newly identified
pathway HMGB1/RAGE/miR221/222 may represent an effective way of tumor escape from immune surveillance that could be used
to develop new therapeutic strategies against anaplastic tumors.
1. Introduction
MicroRNAs (miRNAs) can function as either oncogenes or
tumor suppressor genes via regulation of cell proliferation or
cell death. miRNAs 221 and 222 are two highly homologous
microRNAs that have common targets [1, 2]. Among others,
miR221 and miR222 are overexpressed in thyroid papillary
cancer and in long term cell lines deriving from human papil-
lary cancer [3, 4]. However, the cellular signaling and the way
miRNAs 221 and 222 enhance growth have not been com-
pletely explained in thyroid tumorigenesis. We have recently
demonstrated that inflammatory infiltrates present in papil-
lary cancer are high in HMGB1 that may contribute to tumor
transformation and escape immune surveillance [5–7].
HMGB1 is a DAMP molecule passively released by dam-
aged cells and actively expressed by inflammatory cells [8, 9].
Within the different cellular compartments HMGB1 exerts
different functions. Inside the nucleus it participates in
DNA transcription, recombination, and repair directly or by
increasing the p53, p57, and Rb affinity binding sites. In the
cytoplasm it regulates autophagy and apoptosis by interacting
with mitochondria and with heat shock proteins (HSPB1 and
HSPB7). One of the roles of cytoplasmicHMGB1 is the detec-
tion of nucleic acids and enhancement of nucleic acid binding
TLRs activation. Some TLRs such as TLR 9, 3, and 7 recog-
nize various structures of RNAs and hypomethylated DNA
[10].
Extracellular HMGB1 triggers inflammation by binding
the multiligand receptor RAGE (the receptor for advanced
glycation end products) and Toll-like receptors (TLR 2, TLR
4, and TLR 9) with signalling converge on the AKT activating
pathways [11]. miRNAs 221 and 222 have been found to inter-
act with the AKT pathway by inhibiting translation of the
oncosuppressor PTEN [12].
The PTEN gene dephosphorylates phosphatidylinositol
3,4,5-trisphosphate (PIP3) leading to negative regulation of
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the protein kinase Akt. As well as nonprotein substrates
(PIP3) PTEN might be able to act on protein substrates like
focal adhesion kinases (FAK) and Shc and to control them.
PTEN plays an important role not only in inducing apoptosis
and cell cycle arrest in G1 but also in the regulation of
cell adhesion and migration. Somatic deletions or mutations
of this gene have been identified in many human cancers
including glioblastomas and prostate and thyroid cancer [13,
14]. miRNA221 has been found in serum of thyroid cancer
patients and this correlates with a negative prognosis [15–
17]. miRNAs 221 and 222 have been found to regulate gastric
carcinoma cell growth and radioresistance by suppressing the
action of PTEN [18]. It has been lately demonstrated that cir-
culatingmiRNAs signal through the Toll-like receptors TLR 7
and TLR 8 promoting inflammation and intercellular com-
munication in the tumor microenvironment [19]. Anaplas-
tic thyroid cancers are aggressive tumors [20] that fail to
respond to radiation therapy. Besides hyperexpressing a set of
miRNAs they frequently show mutations in PI3K kinase that
phosphorylates AKT that in turn phosphorylates substrates
involved in cell growth and survival. PTEN that negatively
regulates the PI3K is also mutated inmany cases of anaplastic
and papillary cancer [21, 22].
In this study we analyzed the interactions between extra-
cellular HMGB1 and the repressing action of the miRNAs
221/222 cluster on PTEN oncosuppressor mRNA that may
lead to tumour progression.
2. Materials and Methods
2.1. Reagents. Anti-human PTEN monoclonal antibody was
from DAKO (CA, USA). Anti-RAGE monoclonal antibody
was fromMillipore (CA).
Monoclonal anti-mouse IgG horseradish peroxidase con-
jugate was from GE Healthcare (UK). Human, recombinant
HMGB-1 expressed in E. coli was from Sigma (Missouri,
USA). miRIDIAN hairpin inhibitor, human hsa-miRNA221,
hsa-miRNA222, and miRNA hairpin inhibitor control with
Dy 547 and Dharmafect 1 transfection reagent were pur-
chased from Thermo Fisher Scientific (Lafayette, CO, USA).
Mature miRNA221 sequence was AGCUACAUUGUCUGC-
UGGGUUUC; mature miRNA222 sequence was CUCAGU-
AGCCAGUGUAGAUCCU.
TaqMan miRNA assays (Applied Biosystems, Foster City,
CA, USA).
2.2. Cell Lines. The long term thyroid carcinoma cell lines,
BCPAP and CAL62, obtained by DSMZ (BCPAP n. ACC 273,
CAL62 n ACC 448) in October 2010 [23] were maintained
in RPMI 1640 (GIBCO), supplemented with heat inactivated
10% FCS containing 2mM L-glutamine, where required
10 nM HMGB1 was added to the cultures, at different times.
Cell viability was determined by trypan blue exclusion test,
where required (1 𝜇g/mL) anti-RAGE antibodies were added
to the cultures for 2 h. Antibodies were removed by washings
before the experiments. Cells were kept frozen in nitrogen liq-
uid tanks (2 × 106/1mL FCS, 10% DMSO) and used between
the 4th and 8th passage after revival.
2.3. Knockdown of miRNAs. AntagomiRs against miRNAs
221 and 222, and control oligonucleotide with DY 547,
were obtained fromThermo Fisher Scientific (Lafayette, CO,
USA). AntagomiRs were transiently transfected by using
Dharmafect 1 transfection reagent (ThermoFisher Scientific),
into BCPAP and CAL62 cells, before treatment with HMGB1.
Cells were seeded in 12-well plate at a density of 2 ×
105/well followed by an 18-hour incubation at 37∘C before
transfection. Then culture medium was replaced with 1mL
of antibiotic-free medium containing Dharmafect 1-reagent
(2 𝜇L/mL) and the antagomiRs at 25 nM final concentration
according to manufacturer instructions for 24 h. Controls
with DY 547 and with Dharmafect reagent were included in
the experiments as indicators for transfection efficiencies and
negative controls, respectively. Transfection efficiency was
determined by cytofluorimetric readings in the red light spec-
trum. In our experiments, transfection efficiency (DY 547
positive cells) reached 76%.
2.4. miRNA Relative Quantification by Real Time RT-PCR.
Total RNA was extracted from BCPAP and CAL62 cells with
Trizol reagent (Life technologies), according to the manufac-
turer’s instructions. For the detection of mature miRNA221
andmiRNA222, 50 ng of total RNAwas reversely transcribed
using High Capacity cDNAArchive Kit (Applied Biosystems,
Foster City, CA, USA). Real time PCR was performed using
a miRNA-specific TaqMan assay (Applied Biosystems) in
Applied Biosystems 7900HT Sequence Detection System;
amplifications were performed in triplicate and repeated
twice. The ubiquitously expressed U6b small nuclear RNA
(snRNA) was used for normalization.miRNAs amounts were
quantified by using the ΔΔCt method for relative quantifica-
tion of miRNAs expression.
2.5. Western Blot Analysis. Whole cell lysates were separated
as previously described [6] on 12.5% SDS-polyacrylamide
electrophoresis gel for PTEN. Samples were heat denatured
for 5min, loaded on standard Tris-HCl polyacrylamide gel,
and run on ice at 40V for the stacking gel and 80V for
the running gel. Proteins were transferred onto a previously
activated PVDFmembrane (Bio-Rad, Hercules). Membranes
were then placed in TBS-T and 5% albumin for 1 h and probed
overnight with the specific antibody at 4∘C. At the end of
incubation time, membranes were washed and incubated
with anti-mouse IgG peroxidase conjugated secondary anti-
body (1 : 10000) for 1 h at room temperature.Membranes were
stripped and incubated with anti-actin monoclonal antibody
as a loading control. Signal was detected by autoradiography
(Kodak Biomax) using the chemiluminescent peroxidase
substrate kit (Sigma) and then quantified by densitometric
analysis using quantity-one software (Bio-Rad).
2.6. Statistical Analysis. All determinations were carried out
three times. Data are expressed as means ± SD. Data were
analyzed by Student 𝑡-test. 𝑝 < 0.05 was considered statis-
tically significant.
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Figure 1: Expression of miR221 and miR222 in CAL62 and BCPAP
cells before and after treatment with HMGB1. CAL62 cells (a) and
BCPAP cells (b) were cultured for 24, 48, and 72 h, with or without
10 nMHMGB1 which was added to the culture medium. Expression
levels ofmiRswere detected by real time RT-PCR.miRNAs amounts
were quantified by using the ΔΔCt method and normalized with
U6b small nuclear RNA (snRNA) expression. Histograms represent
the mean values of 3 independent experiments (±SD).
3. Results
3.1. HMGB1 Increases Expression of miRNA221 and
miRNA222 and Decreases Expression of PTEN in CAL62 and
BCPAPCells. HMGB1 is a DNA-binding nuclear protein that
is released passively during cell death or actively following
cytokine stimulation. It is abundantly found in the papillary
tumor microenvironment where it has been shown to
stimulate growth and chemotaxis of both immune and cancer
cells. In order to investigate a possiblemode of thyroid cancer
cell proliferation induced by extracellular HMGB1, expres-
sion of miRNA221 and miRNA222 in CAL62 and BCPAP
cells was assessed by PCR after addition of HMGB1 for
24, 48, and 72 h. The concentration of 10 nM HMGB1 was
chosen according to our previous studies [3] and to internal
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Figure 2: Expression of miR221 and miR222 in anti-RAGE pre-
treated CAL62 and BCPAP cells with or without HMGB1 for 24 h.
CAL62 (a) and BCPAP cells (b) were treated with anti-RAGE
antibody and then cultured with 10 nMHMGB1 for 24 h. Expression
levels of mirR 221 and 222 were detected by RT-PCR and quantified
with the ΔΔCt method. Histograms represent the mean values of 3
independent experiments (±SD).
dose-response controls performed on different cell lines
and in primary cultures obtained from papillary cancer and
nonneoplastic lesions (6).
Figure 1 shows that treatment with HMGB1 increases
expression of miRNAs 221 and 222 significantly in both cell
lines (𝑝 < 0.01).
In order to show if the above effect was mediated by
HMGB1-RAGE binding, cells were treated with anti-RAGE
antibody and then stimulated with HMGB1 for 24 h. Figure 2
shows that when RAGE is blocked by anti-RAGE, the pres-
ence of HMGB1 does not significantly increase miR221 and
miR222 expression in both CAL62 cells and BCPAP. Overall
the results indicate that induction of miR221 andmiR222, the
latter at a minor extent, is RAGE dependent.
At the light of HMGB1 effect played on miRNAs 221 and
222 expression and considering that they have been shown to
inhibit PTENmRNA inmany human cancers, we studied the
expression of PTEN after treatment of cells with HMGB1 for
up to 72 h.
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Figure 3: Effect of HMGB1 on PTEN expression in CAL62 and
BCPAP cells. CAL62 and BCPAP cells were cultured for 24, 48, and
72 h, with or without 10 nMHMGB1 which was added to the culture
medium. Expression levels of protein PTEN 55 kDa was detected
by western blot in whole cell lysates (𝑝 < 0.05). Representative
experiment of 3 different western blots.
Interestingly PTEN protein levels shown in Figure 3
constantly decrease after addition of HMGB1 in both CAL62
and BCPAP cells compared with the controls (𝑝 < 0.05).
When RAGE receptors are blocked by anti-RAGE anti-
bodies, HMGB1 fails to induce PTEN decrease as demon-
strated by cytofluorimetric analysis shown in Supplementary
Figure 1 (see Supplementary Material available online at
http://dx.doi.org/10.1155/2015/512027).
3.2. AntagomiRs 221 and 222 Increase Expression of PTEN
in CAL62 and BCPAP Cells. In order to demonstrate that
miRNA221 and miRNA222 were linked with PTEN function
in CAL62 and BCPAP cells we delivered specific antagomiRs
and determined miRs expression.
Figure 4 shows that cotransfection of antagomiRs 221 and
222 in CAL62 was able to reduce expression of miRNA221
by 44.5% and miRNA222 by 25%. Reduction of miR221 and
miR222 expression in BCPAP cells was, respectively, of 66.6%
and 30%. In order to show that HMGB1 was not able to
increase miRs expression when miRs were blocked by anta-
gomiRs we treated transfectant cells with HMGB1 for 24 h
and obtained a similar reduction to that obtained in trans-
fectant cells without HMGB1 treatment (Figure 4).This result
shows thatHMGB1 is responsible formiR221/222 overexpres-
sion.
The next set of experiments was designed to show if
the action of HMGB1 on miR221/222 cluster was functional
on PTEN, which is a known target of miR221 and miR222.
For this reason, transfectant cells were grown for up to 72 h
in presence of 10 nM HMGB1 and PTEN expression was
determined by western blot. As shown in Figure 5, HMGB1
did not significantly reduce PTEN expression in transfectants
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Figure 4: Expression of miR221 and miR222 after transfection
with antagomiRs 221/222 and in transfectants after treatment with
HMGB1.Q-RT-PCRanalysis ofmiR221 andmiR222 level expression
in CAL62 and BCPAP cells transfected with miR221 and miR222
antagonists (transfectants: miR221−/miR222−) or negative control
(CTR), at 25 nM final concentration for 24 h, where indicated
transfectants were treated with 10 nM HMGB1 for 24 h. Data were
normalized with U6b small nuclear RNA (snRNA) expression and
reported as mean ± SD of 3 experiments (𝑝 < 0.01).
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Figure 5: PTEN expression in CAL62 and BCPAP cells transfected
with antagomiRs 221/222 and then treated or not with HMGB1.
Effect of antagomiRs 221 and 222 on PTEN expression. CAL62
and BCPAP cells were transfected with antagomiRs 221 and 222
(transfectants). 24 h after transfection, cells were cultured for 24, 48,
and 72 h with or without the addition of 10 nM HMGB1. At the end
of incubation times, the cell lysates were harvested and subjected
to western blot analysis for PTEN protein expression. 𝑝 < 0.01
versus parental cells and transfectants; 𝑝 < 0.01 versus parental cells
and transfectants with HMGB1; transfectants versus transfectants
with HMGB1 were not statistically significative. Representative
experiment of 3 different western blots.
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Figure 6: Effect of HMGB1 on the proliferation rate of parental and transfected CAL62 and BCPAP cells. 105 parental cells and transfectants
were seeded into a 6-well plate at time 0 with or without 10 nM HMGB1. At the indicated times cell number and cell viability of each well
were counted with a haemocytometer. Data represent the mean values of 3 independent experiments (±SD). 𝑝 < 0.01 versus transfectants
and parental cells and versus transfectants and transfectants treated with HMGB1.
indicating that it interacts with PTEN through the miRNAs
221/222 cluster.
3.3. HMGB1 Increases Growth of CAL62 and BCPAP Cells
While AntagomiRs 221 and 222 Inhibit It. Figure 6 shows
growth curves of both parental and transfectant CAL62 and
BCPAP cells. Addition of 10 nM HMGB1 to CAL62 cells for
24, 48, and 72 h increases growth in a significative way. A
similar trend but a much higher increase was obtained in
BCPAP cells cultured in presence of HMGB1.
CAL62 cells transfected with antagomiRs 221 and 222
show a time dependent decrease of growth (from 13.4% at
24 h to 31.2% at 72 h) compared with controls. HMGB1 added
to the CAL62 and BCPAP transfectants reduces growth,
respectively, of 38.5% and 42% at 24 h, 50% and 48.6% at 48 h,
and 68% and 60% at 72 h. The decrease of growth in trans-
fected cells is due to the high rate of cell death induced by the
blockage of miR221/222. This has been reported in many cell
lines [18]. InterestinglyHMGB1 induces a higher rate of death
into transfected cells compared with parental cells (shown in
Supplementary Figure 2).
4. Discussion
Following our previous study demonstrating that HMGB1
increases miR221 and miR222 expression in short term pri-
mary cultures of papillary cancer cells compared with normal
cells obtained from contralateral thyroid lobe and with cells
from patients with nonneoplastic lesions, we report here that
HMGB1 induces miRNAs 221 and 222 hyperexpression in
both differentiated (BCPAP) and anaplastic (CAL62) thyroid
cancer cell lines. In turn miR221/222 cluster inhibits the
tumor suppressive role of PTEN.We are reporting here for the
first time that exogenousHMGB1 decreases PTEN expression
in thyroid cell lines.
It is known that HMGB1 proteins are involved in tran-
scription regulation through many different epigenetic pro-
cesses [24]. In a variety of human tumors elevated levels of
HMGs are associated with a poor prognosis and with tumor
invasion and metastasis [25]. When HMGB1 proteins are
released in the tumor microenvironment by immune cells,
they act as both autocrine and paracrine messengers. They
bind TLR 2, TLR 4, and RAGEs present on immune cells and
on tumor cells [26, 27] and activate NF𝜅B, PI3K/Akt, and
other activating pathways. It is known that miRNAs 221 and
222 enhance Akt phosphorylation through downregulation
of PTEN in many human cancers [28].
HMGB1 is required for the immune response to nucleic
acids by activating intracytoplasmic TLR 3, 7, and 9. An
interesting colocalization of HMGB1 and TLR 9 with an
endosomal marker EEA1 has been shown in quiescent cells
upon stimulation with oligodeoxynucleotides (CpG-ODN)
[29]meaning that cytoplasmicHMGB1 is able to interact with
nucleotides. HMGB1 has been shown to promote prolifer-
ation and migration of different tumor cells via its known
receptor TLR 4 [30]. We are reporting here that HMGB1
action on both BCPAP and CAL62 cells is specific and is
due to RAGEs intracellular pathways. The blocking action
of anti-RAGE antibody prevents both PTEN reduction and
increase of cellular proliferation (not shown). The data we
obtained with cells transfected with antagomiRs 221 and 222
and treated with HMGB1 suggest that stimulation of RAGEs
by HMGB1 leads to inactivation of oncosuppressor PTEN
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through an interaction with miRNAs 221/222. The inactivity
ofmiRNAswas able to blockHMGB1 related growth increase,
meaning that blocking miRNAs 221 and 222 overrides
HMGB1 effects on PTEN expression and cell growth. To our
knowledge this is the first time it has been shown that the
newly identified pathway HMGB1/RAGE/miR221/miR222
may connect immune system with cancer. Although we have
been able to establish that RAGE signaling can regulate the
expression of miR221/222, interactions between intracellular
RAGE signaling and miR221/222 require further investiga-
tion.
5. Conclusions
Our resultsmay help the finding of new therapeutic strategies
for the treatment of anaplastic thyroid cancer and they may
provide new prognostic factors that could address the right
therapeutic strategy in papillary cancer.
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